Who We Are
Our company is engaged in the research, development, and manufacturing of pharmaceutical products for the treatment of complex diseases. We develop state-of-the-art, safe, effective, and affordable drugs.
We take on the challenge of transforming people’s lives by improving their quality of life. Our manufacturing processes and working methodologies are continuously audited by international technical teams, in accordance with the requirements of the main regulatory entities of the countries where we market our products.
A Megalabs Company
We are part of the pharmaceutical group Megalabs, with subsidiaries throughout Latin America and a regional benchmark in drug development and processing. Megalabs is characterized by the implementation of state-of-the-art technology, continuous technical updating, and permanent orientation towards world-class standards.
High Specialization
We are a highly specialized pharmaceutical company dedicated to the research, development, and manufacturing of chemical synthesis and biotechnological products. Our focus is the development of state-of-the-art drugs, targeted at specific molecular targets for complex and highly sensitive conditions. At Iclos we aim at improving people’s quality of life, allowing early and universal access to medicines at a reasonable cost, ensuring their efficacy and safety.
We develop drugs for treating conditions in the areas of oncology, transplants, and autoimmunity. We develop bioequivalent and biosimilar products under strict manufacturing protocols.
Regional Positioning
We are one of the most advanced laboratories in the region, present throughout the continent. We market our products in 16 countries in Latin America and we have commercial alliances in Europe and Asia.
We seek to consolidate our leadership in the drugs we develop in new markets. This objective is carried out through research and innovation processes based on ethics and responsibility.
We have initiated clinical research activities in Brazil, and project the development of new products in the Mexican market.
International Support
We ensure compliance with international Good Manufacturing Practice regulations and a policy of continuous improvement. We have been certified by the most demanding regulatory bodies in Latin America, as well as the European health authority, EMA, for the production of immunosuppressants.
Innovation Processes
How we work allows us to continuously create knowledge. Biosimilar development processes involve research institutions, such as clinical studies, as well as ongoing interaction with the region’s main regulatory entities. This gained experience provides us a better understanding of the critical parameters of each process.
The quality of the products we manufacture is guaranteed by three analytical laboratories (microbiological, physical-chemical and biological control). Our Quality Assurance Department guarantees compliance with international Good Manufacturing Practice regulations and a policy of continuous improvement.
Our People
We have highly qualified and internationally trained professional teams that allow us to be up to date on emerging regulatory frameworks, as well as prepared for future challenges.
Research, Development and Production
We have a professional team focused on the research, development, and manufacturing of pharmaceutical products for certain conditions. More than 70% of our members work in development centers and production plants.
Our Commercial Team
Iclos’ commercial department comprises professionals who are trained and knowledgeable in certain conditions and their treatments. Our commercial team maintains a fluid interaction with health professionals, aiming at providing certainties and building trusted relationships.
Iclos LATAM
Iclos LATAM is a Megalabs company that seeks to consolidate its leadership in biological and chemical synthesis products in Latin America and new markets. This objective is carried out through research and innovation processes based on ethics and responsibility. The organization has qualified professional teams, thus enabling it to meet the highest international standards.